title: Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy.
abstract: OBJECTIVE
  Locally advanced cervical cancer (LACC) is one of the leading health problems of the developing countries. We present long-term outcomes of treatment with a concomitant chemobrachyradiotherapy followed by consolidation chemotherapy regimen.
  
  
  METHODS
  We treated 118 patients with LACC (International Federation of Gynecology and Obstetrics stages IB2-IVA) with external radiotherapy (50 Gy in 25 fractions) and concomitant chemobrachyradiotherapy (low-dose rate). Chemotherapy was applied during brachyradiotherapy (cisplatin on day 1 in combination with 24-hour infusion of ifosfamide and mesna uroprotection). Four cycles of consolidation chemotherapy were given starting 4 weeks after the second concomitant chemobrachyradiotherapy cycle.
  
  
  RESULTS
  After median follow-up period of 99.3 months, we observed acceptable acute and late toxicity, local control rate of 97.5%, and an overall survival of 74.6% at 96 months.
  
  
  CONCLUSIONS
  Chemobrachyradiotherapy regimen followed by consolidation chemotherapy described in this article is a valuable treatment option for LACC.
authors.affiliation: *Department of Oncology, University Hospital Split, Split, Croatia; †Department of Oncology, University Hospital Mostar, Mostar, Bosnia and Herzegovina; ‡Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany; and §Department of Pathology, University Hospital Split, Split, Croatia.
authors.forename: Branka
authors.initials: B
authors.lastname: Petrić Miše
authors.forename: Tihana
authors.initials: T
authors.lastname: Boraska Jelavić
authors.forename: Ante
authors.initials: A
authors.lastname: Strikic
authors.forename: Darijo
authors.initials: D
authors.lastname: Hrepić
authors.forename: Krešimir
authors.initials: K
authors.lastname: Tomić
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Hamm
authors.forename: Snježana
authors.initials: S
authors.lastname: Tomić
authors.forename: Tomislav
authors.initials: T
authors.lastname: Prskalo
authors.forename: Eduard
authors.initials: E
authors.lastname: Vrdoljak
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001918:Brachytherapy / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D060830:Consolidation Chemotherapy / Q000009:adverse effects; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
chemical_list: D002945:Cisplatin; D007069:Ifosfamide